Overview
With over $550 million in assets under management, H.I.G. BioHealth Partners invests in a broad range of healthcare companies across multiple sectors and stages of development. Our seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. We invest in companies developing novel products for significant unmet medical needs more >
Portfolio
Recent News
- Thu, Apr 28th, 2022 — Nevakar Injectables Receives U.S. FDA Approval of Ready-to-Use Ephedrine Injection in a Prefilled…
- Fri, Apr 15th, 2022 — Click Therapeutics Closes $15 Million Debt Financing from Silicon Valley Bank
- Tue, Mar 8th, 2022 — On Target Laboratories and Mauna Kea Technologies Announce a Novel Clinical Research and Product…
- Wed, Mar 2nd, 2022 — H.I.G. Capital Expands BioHealth Team with Addition of Gwen Watanabe
- Tue, Feb 8th, 2022 — Leiters Announces Facility Acquisition to Increase Capacity, Accommodate Growth and Expand…
- Tue, Jan 18th, 2022 — Augmented Reality Pioneer Augmedics Announces New CEO in Support of Accelerating Growth
- Tue, Dec 14th, 2021 — Zerigo Health Expands Board of Directors
- Thu, Dec 9th, 2021 — Zerigo Health Appoints Helen Calvin as President and Chief Commercial Officer
- Mon, Nov 29th, 2021 — On Target Laboratories Announces FDA Approval of CYTALUX™ (pafolacianine) injection for…
- Thu, Nov 18th, 2021 — BIOVECTRA mRNA Vaccine and Bio-manufacturing Facility Announced